Assertio Therapeutics, Inc. (NASDAQ:ASRT) is reporting second quarter financial results on Friday 7th August 2020, before market open.
According to analysts surveyed by Thomson Reuters, ASRT is expected to report 2Q20 loss of $ 0.03 per share from revenue of $ 25.33 million.
For the full year, analysts anticipate top line of $ 100.22 million, while looking forward to income of $ 0.11 per share bottom line.
Previous Quarter Performance
Assertio Therapeutics, Inc. unwinded income for the first quarter of $ 0.10 per share, from the revenue of $ 20.92 million. The quarterly earnings reduced 56.52 percent while revenues reduced 63.89 percent compared with the same quarter last year.
Street analysts expected Assertio Therapeutics, Inc. to report loss of $ 0.08 per share on revenue of $ 11.30 million for the first quarter. The bottom line results beat street analysts by $ 0.18 or 225.00 percent, at the same time, top line results outshined analysts by $ 9.62 million or 85.13 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Assertio Therapeutics, Inc.
Stock Performance
The company has a market capital of $ 96.97 million and is part of the Healthcare sector and Drug Manufacturers – Specialty & Generic industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”ASRT” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
Assertio Therapeutics, Inc. will be hosting a conference call at 8:30 AM eastern time on 7th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.assertiotx.com
Assertio Therapeutics, Inc., a specialty pharmaceutical company, provides medicines in neurology, orphan, and specialty areas in the United States. The company offers Gralise (gabapentin), a once daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug for the acute treatment of migraine attacks; and Zipsor (diclofenac potassium liquid filled capsules), a non-steroidal anti-inflammatory drug for treating mild to moderate acute pain. It also provides NUCYNTA ER (tapentadol extended release tablet), a product for the management of pain severe enough to require daily, around-the-clock, and long term opioid treatment, including neuropathic pain related to diabetic peripheral neuropathy in adults; and NUCYNTA IR (tapentadol), a product for the management of moderate to severe acute pain in adults.
